Joshua T. Cohen, PhD

Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024.

This study's findings showed that diabetes care remained suboptimal among many patients with multiple chronic conditions and that patient outcomes varied by multimorbidity profile.

This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.

Building negative incentives into value-based insurance design programs to discourage use of low-value care will involve a number of challenges.